SPONSOR
He Huang
Total Trials
3
Recruiting
3
Phases
EARLY_Phase 1, Phase 1
Conditions studied: Acute Lymphoblastic LeukemiaNon-hodgkin LymphomaRelapse/Refractory Multiple MyelomaLupus Nephritis
He Huang is a clinical research sponsor with 3 registered studies on ClinicalTrials.gov, of which 3 are actively recruiting participants. Research covers conditions including Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma, Relapse/Refractory Multiple Myeloma, Lupus Nephritis.
The trial portfolio spans EARLY_Phase 1, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — He Huang
How many clinical trials has He Huang sponsored?
ClinicalMetric currently tracks 3 clinical trials sponsored by He Huang, of which 3 are actively recruiting participants. These trials cover conditions including Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma, Relapse/Refractory Multiple Myeloma. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does He Huang research focus on?
He Huang clinical trials span Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma, Relapse/Refractory Multiple Myeloma, Lupus Nephritis. The research pipeline includes EARLY_Phase 1, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a He Huang clinical trial?
To participate in a He Huang trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all He Huang trials with current recruitment status updated daily.
Clinical Trials by He Huang
NCT04227015 EARLY_Phase 1
Recruiting
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
Acute Lymphoblastic Leukemia
NCT06084962 Phase 1
Recruiting
A Study of DeepTag-GPRC5D Targeted CAR-T Cells Therapy for Refractory/Relapsed Multiple Myeloma
Relapse/Refractory Multiple Myeloma
NCT06785519 EARLY_Phase 1
Recruiting
CD19/BCMA CAR-T Cell Therapy for Refractory/Relapsed Lupus Nephritis
Lupus Nephritis
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology